UK Breaks New Ground: National Guideline Recommends Pharmacogenomic Testing for All Patients Before Prescribing Clopidogrel
7 January 2026
The UK has taken a major step toward precision medicine with the release of a new national clinical guideline recommending pharmacogenomic testing for all patients before prescribing the antiplatelet drug clopidogrel, a first in the country’s healthcare landscape.¹
What's New?
On 4 December 2025, the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (UK CERSI-PGx) published a clinical guideline advising that every patient who may be prescribed clopidogrel should undergo genetic testing for CYP2C19 variants where testing is available.¹
This recommendation goes beyond previous UK advice, which focused primarily on high-risk patients, such as those with a history of stroke and instead, moves toward a more inclusive, proactive approach.
Why CYP2C19 Matters
Clopidogrel, a commonly prescribed antiplatelet drug, must be metabolised by the CYP2C19 enzyme in the liver to become active. However, genetic variants in the CYP2C19 gene can drastically affect this metabolism:
- Some people have variants leading to reduced or no enzyme activity, meaning clopidogrel may not work effectively for them.
- Others metabolise the drug normally and benefit as expected.
Research shows that a substantial percentage of the UK population has lower CYP2C19 activity — about 20–30% in White individuals and up to 50–60% in some people of Asian descent — highlighting the potential scale of the issue.¹
What the Guideline Recommends
The guideline strongly encourages² :
- Pre-emptive pharmacogenomic testing for CYP2C19 variants before initiating clopidogrel.
- Avoiding clopidogrel in patients with intermediate or poor metaboliser status.
- Using alternative antiplatelet medications, such as prasugrel or ticagrelor, where appropriate.
- Incorporating genetic testing into clinical workflows — including eligibility criteria, testing logistics, and result interpretation.
As the guideline states, genetic testing should be used where available, and in settings without access to testing, clinicians should continue to follow existing best-practice recommendations.²
How This Fits into Broader Pharmacogenomics Trends
This initiative aligns with global efforts to integrate pharmacogenomics into everyday clinical care. International groups like the Clinical Pharmacogenetics Implementation Consortium (CPIC) already advocate genotype-guided prescribing for drugs affected by genetic variability, including clopidogrel.³
In the UK, earlier guidance by bodies like NICE suggested phased implementation, particularly for stroke patients.⁴ The new guideline represents a significant scaling up of that vision.
Benefits of Genotype-Guided Prescribing
Proponents of pharmacogenomic testing point to several advantages³:
- Improved drug effectiveness: Ensures patients receive medications the body can properly activate.
- Reduced adverse effects: Genetic mismatches increase the risk of complications or therapy failure.
- Potential healthcare savings: Optimised prescribing may lower hospitalisations and ineffective treatments.
What This Means for Patients and Clinicians
For Patients:
If you or someone you know is being considered for clopidogrel therapy, ask about CYP2C19 genetic testing. It could influence not just the drug choice but also the overall safety and effectiveness of treatment.
For Clinicians:
This guideline highlights the need for systems that support genetic testing workflows, including result turnaround, interpretation, and actionable recommendations in electronic health records.
Looking Ahead
This guideline marks a pivotal moment in UK medicine, one that could serve as a model for integrating pharmacogenetics into wider therapeutic areas. Continued research and infrastructure development will be key to realising its full benefits.
Clopidogrel is one of the key medications included in the PRECISE Pharmacogenomics (PGx) Test, allowing individuals and clinicians to understand whether the drug will work as intended or if an alternative may be safer and more effective.
If you would like to know how your genes may influence your response to clopidogrel or more than 500 other clinically relevant medications, speak to us today about the PRECISE PGx Test.
Reference List
- The Pharmaceutical Journal. UK introduces national recommendation for pharmacogenetic testing before clopidogrel prescribing. Pharm J. 2025;317(8004). doi:10.1211/PJ.2025.1.389409
- Dello Russo C, Frater I, Kuruvilla R, et al. CYP2C19 genotype testing for clopidogrel: a guideline developed by the UK Centre of Excellence for Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx). Br J Clin Pharmacol. 2025. doi:10.1002/bcp.70370
- Patel TJ, Wehbe E, Hughes S, et al. Implementing CYP2C19-guided clopidogrel therapy: a scoping review of pharmacogenomic testing services. Pharmacogenomics J. 2025;25:12. doi:10.1038/s41397-025-00371-4
- The Pharmaceutical Journal. Pharmacogenetic testing and antiplatelet therapy: clinical implications for practice. Pharm J. 2024;312(7984). doi:10.1211/PJ.2024.1.307759
